NewcelX Enters into Binding Term Sheet to Divest Legacy Mazindol Portfolio (CVR), Providing for Upfront Cash, Equity Ownership and Up to $55 Million in Potential Milestone Payments

NewcelX Ltd. (Nasdaq: NCEL) announced a binding term sheet to divest its Mazindol asset portfolio to REA Holdings Inc. for $500,000 upfront ($30,000 cash and $470,000 in equity representing 9.4% stake), plus up to $55 million in potential milestone payments and tiered royalties of 2-8% on global net sales. The divestiture allows NewcelX to focus on its core cell-therapy pipeline for Type 1 Diabetes while preserving potential value for CVR holders.